Taken together, these data allowed us to hypothesize that the combination of genetic NR2F6 ablation and anti-PD-L1 (aPD-L1) immunotherapy with antitumor immune responses elicited by PTT may exert a strong synergistic effect, and thus present an effective strategy for HCC treatment. This evidence concerns the gene NR2F6 and hepatocellular carcinoma.